Cite
HARVARD Citation
Aakko, S. et al. (n.d.). P380: EX VIVO IMMUNE ACTIVATION WITH THE MACROPHAGE-TARGETING IMMUNOTHERAPY, ANTI-CLEVER-1 ANTIBODY BEXMARILIMAB, IN ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME. HemaSphere. pp. 280-281. [Online].